全文获取类型
收费全文 | 2441311篇 |
免费 | 177429篇 |
国内免费 | 3660篇 |
专业分类
耳鼻咽喉 | 33034篇 |
儿科学 | 78634篇 |
妇产科学 | 64324篇 |
基础医学 | 360394篇 |
口腔科学 | 65415篇 |
临床医学 | 220549篇 |
内科学 | 475666篇 |
皮肤病学 | 52886篇 |
神经病学 | 194306篇 |
特种医学 | 90827篇 |
外国民族医学 | 490篇 |
外科学 | 367001篇 |
综合类 | 48759篇 |
现状与发展 | 13篇 |
一般理论 | 982篇 |
预防医学 | 191078篇 |
眼科学 | 56885篇 |
药学 | 181660篇 |
12篇 | |
中国医学 | 4778篇 |
肿瘤学 | 134707篇 |
出版年
2021年 | 20665篇 |
2019年 | 21241篇 |
2018年 | 29100篇 |
2017年 | 21862篇 |
2016年 | 24465篇 |
2015年 | 27637篇 |
2014年 | 38948篇 |
2013年 | 58129篇 |
2012年 | 80776篇 |
2011年 | 86014篇 |
2010年 | 50693篇 |
2009年 | 48018篇 |
2008年 | 80496篇 |
2007年 | 85702篇 |
2006年 | 86248篇 |
2005年 | 83746篇 |
2004年 | 80043篇 |
2003年 | 76903篇 |
2002年 | 74414篇 |
2001年 | 109586篇 |
2000年 | 112070篇 |
1999年 | 94406篇 |
1998年 | 28075篇 |
1997年 | 24556篇 |
1996年 | 24768篇 |
1995年 | 23417篇 |
1994年 | 21534篇 |
1993年 | 20337篇 |
1992年 | 72482篇 |
1991年 | 70526篇 |
1990年 | 68784篇 |
1989年 | 66011篇 |
1988年 | 60689篇 |
1987年 | 59465篇 |
1986年 | 55521篇 |
1985年 | 53393篇 |
1984年 | 39745篇 |
1983年 | 33804篇 |
1982年 | 20417篇 |
1979年 | 36139篇 |
1978年 | 25922篇 |
1977年 | 21504篇 |
1976年 | 20566篇 |
1975年 | 22023篇 |
1974年 | 26367篇 |
1973年 | 25017篇 |
1972年 | 23365篇 |
1971年 | 22162篇 |
1970年 | 20352篇 |
1969年 | 19434篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
161.
Elhaji Youssef A.; Stoica Ileana; Dennis Sheldon; Purisima Enrico O.; Lumbroso Rose; Beitel Lenore K.; Trifiro Mark A. 《Human molecular genetics》2006,15(9):1561
Human Molecular Genetics (2006) 15, 921931; 相似文献
162.
163.
C.A. AMEZCUA H.R. MACDONALD† C.A. LUM W. YI‡ L.I. MUDERSPACH† L.D. ROMAN† & J.C. FELIX† 《International journal of gynecological cancer》2006,16(3):1336-1341
In this study, we examine the prevalence of finding isolated tumor cells (ITCs) in negative lymph nodes of endometrial cancer patients using immunohistochemistry. Seventy-six endometrial cancer patients with lymph nodes histologically negative for metastatic disease were examined. Nodal tissue sections were stained with anticytokeratin antibodies AE-1 and CAM 5.2. Nodes with single or groups of cells (two to four cells) < or =0.2 mm and showing cytokeratin reactivity were positive for ITCs. Findings were compared to features of the primary tumor and patient outcome. ITCs were present in 31 of 1712 lymph nodes. Fifteen (19.7%) patients had ITC-positive nodes. ITCs involved only pelvic nodes in nine cases, only para-aortic nodes in five cases, and pelvic and para-aortic in one case. Tumor in adnexa was the only pathologic feature associated with nodal ITCs (P= 0.0485). All 15 patients with nodal ITCs were alive at follow-up. One (6.7%) patient suffered recurrent disease but was alive at last encounter. Disease recurred in 5 (8.8%) of 57 patients without nodal ITCs. Two are alive without disease, two alive with disease, and one died from her cancer. In summary, a significant proportion of endometrial cancer patients have ITCs detected by immunohistochemistry in histologically negative regional lymph nodes. 相似文献
164.
PURPOSE: Concern over stigma as a consequence of genetic testing has grown in response to the recent increase in genetic research and testing resulting from the Human Genome Project. However, whether a genetic or hereditary basis necessarily confers a stigma to a condition remains unexamined. METHODS: We performed a qualitative interview study with 86 individuals with one of four conditions: deafness or hearing loss, breast cancer, sickle cell disease, and cystic fibrosis. The first two groups were divided approximately between people who ascribed their conditions to a genetic or hereditary cause and those who did not. RESULTS: Respondents interpreted genetic or hereditary causes and nongenetic causes in a variety of ways. Subjects with breast cancer reported the most consistently negative interpretation of genetic cause. This response concerned future ill health, not an enduring sense of stigma. Deaf and hard of hearing subjects provided the most consistently positive comments about a genetic or hereditary basis to their condition, casting familial hearing loss as a vital component of group and individual identity. Respondents with sickle cell disease and cystic fibrosis offered similar and positive interpretations of the genetic cause of their condition insofar as it meant their conditions were not contagious. CONCLUSIONS: Although some subjects report feeling stigmatized as a result of their condition, this stigmatization is not uniformly associated with the condition's cause, genetic or otherwise. Instead, stigma emerges from a variety of sources in the context of the lived experience of a particular condition. 相似文献
165.
C G Arruda J M Aldrighi L A Bortolotto I N Alecrin J A F Ramires 《Gynecological endocrinology》2006,22(10):557-563
BACKGROUND: Arterial hypertension and postmenopausal reduction of estrogen levels may be involved in modifications of the stiffness of large arteries. OBJECTIVES: To evaluate the pulse-wave velocity (PWV) and indirectly the arterial stiffness in hypertensive postmenopausal women submitted to hormone therapy with estradiol alone or combined with norethisterone acetate. SUBJECTS: Forty-five hypertensive postmenopausal women were double-blindly, randomly assigned to three arms of treatment: placebo (group I); estradiol 2 mg/day (group II); or estradiol 2 mg/day and norethisterone acetate 1 mg/day (group III). METHODS: Arterial stiffness was assessed from PWV measurements of the common carotid and femoral arteries (CF-PWV) and the common carotid and radial arteries (CR-PWV) obtained using the automatic Complior(R) device, taken at baseline and after 12 weeks of treatment. RESULTS: After the 12-week treatment, values of CF-PWV and CR-PWV were not significantly different (p = 0.910 and p = 0.736, respectively) among the groups. Systolic blood pressure showed a positive correlation with CF-PWV in groups II and III (p = 0.02 and p < 0.001, respectively). CONCLUSIONS: PWV and arterial stiffness in postmenopausal hypertensive women did not reduce over a 12-week treatment with estradiol alone compared with the same period of treatment with estradiol combined with norethisterone acetate. 相似文献
166.
The aim of our study was to determine the incidence, timing, and severity of vaginal stenosis in patients with carcinoma of the cervix who had received pelvic and/or vaginal radiotherapy as part of their treatment. We also sought to determine if there were any predisposing factors for the development of stenosis. A retrospective chart review was undertaken for all the patients diagnosed with carcinoma of the cervix between January 1, 1990, and December 31, 2000 and treated with pelvic and/or vaginal radiation at Westmead Hospital. Since January 1, 1990, data regarding vaginal stenosis has been prospectively recorded on all the patients. Data collected included patient demographics, stage of disease, treatments administered, and incidence, timing, and severity of vaginal stenosis. One hundred and eighty-eight patients were treated. Mean age was 58.6 years. Thirteen percent of patients had stage IB disease, 45% had stage II disease, 39.5% had stage III disease, and 1.5% had stage IV disease. One hundred and seventy-nine patients returned for follow-up, and data regarding vaginal toxicity were available in 98%. Twenty-seven percent had grade 1 toxicity (partial stenosis or shortening but not complete occlusion), and 11% had grade 2 (complete occlusion). Stenosis of any grade was noted at a mean of 9.6 months and median of 7.5 months (range, 26 days-5.6 years) from completion of treatment. The only prognostic factor associated with increased risk of stenosis was age greater than 50 years (odds ratio 2.26). Vaginal stenosis is a common complication of pelvic and vaginal radiotherapy, occurring in 38% of patients. Stenosis occurs most often in the first year after treatment. Patients over the age of 50 are most at risk. 相似文献
167.
168.
169.
170.